Protalix BioTherapeutics, Inc.
PLX
$2.80
-$0.05-1.75%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 73.74% | 73.60% | -61.59% | -60.91% | 21.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.74% | 73.60% | -61.59% | -60.91% | 21.69% |
| Cost of Revenue | -56.12% | 71.16% | 53.81% | -15.66% | 269.46% |
| Gross Profit | 779.26% | 75.79% | -86.11% | -82.38% | -73.79% |
| SG&A Expenses | -27.61% | -29.29% | -13.57% | 0.00% | 33.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.63% | 14.19% | 8.51% | -28.58% | 44.90% |
| Operating Income | 228.39% | 311.50% | -111.88% | -97.48% | -125.05% |
| Income Before Tax | 213.85% | 323.56% | -111.56% | -61.21% | -100.19% |
| Income Tax Expenses | 315.18% | 356.39% | -122.40% | -170.77% | -172.08% |
| Earnings from Continuing Operations | 207.45% | 274.73% | -111.39% | -46.76% | -61.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 207.45% | 274.73% | -111.39% | -46.76% | -61.60% |
| EBIT | 228.39% | 311.50% | -111.88% | -97.48% | -125.05% |
| EBITDA | 242.27% | 373.07% | -110.18% | -108.08% | -138.83% |
| EPS Basic | 211.18% | 271.88% | -110.45% | -15.41% | -13.82% |
| Normalized Basic EPS | 217.72% | 319.46% | -110.61% | -26.96% | -41.07% |
| EPS Diluted | 176.44% | 178.01% | -114.33% | -15.41% | -13.82% |
| Normalized Diluted EPS | 179.20% | 331.25% | -113.14% | -26.96% | -41.07% |
| Average Basic Shares Outstanding | -3.30% | 1.75% | 9.16% | 27.06% | 41.99% |
| Average Diluted Shares Outstanding | 43.67% | -3.06% | -11.89% | 27.06% | 41.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |